Develops and manufactures biosimilar medicines to improve patient access to affordable biologics globally.
Alvotech, headquartered in Reykjavik, Iceland, specializes in the development and global manufacturing of biosimilar medicines aimed at improving patient access to affordable treatments worldwide. The company's diverse portfolio spans therapeutic areas including autoimmune diseases, eye disorders, bone conditions, and cancer. Alvotech's flagship programs include AVT02, a high concentration biosimilar of Humira, targeting inflammatory conditions such as rheumatoid arthritis and psoriasis.
Another key product, AVT04, mirrors Stelara's therapeutic benefits for treating inflammatory disorders like Crohn's disease and ulcerative colitis. Additionally, Alvotech is advancing AVT06, a biosimilar to Eylea, designed for conditions such as age-related macular degeneration and diabetic retinopathy. AVT03, currently in pre-clinical stages, aims to replicate the effects of Xgeva and Prolia to prevent bone fractures and bone loss in cancer patients.
Established in 2013, Alvotech continues to expand its biosimilar pipeline with products like AVT05, targeting inflammatory conditions, and AVT23, nearing completion for treating nasal polyps. With a commitment to innovation and therapeutic advancement, Alvotech strives to make a significant impact in global healthcare by providing high-quality biosimilar alternatives to complex and costly therapies.